Creative Planning’s Nurix Therapeutics NRIX Stock Holding History

Creative Planning’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$296K	Buy	19,121 +1,017	+6%	+$16.9K	﹤0.01%	3436
2025 Q4	$343K	Buy	18,104 +7,070	+64%	+$102K	﹤0.01%	3152
2025 Q3	$102K	Sell	11,034 -5,375	-33%	-$55.8K	﹤0.01%	3667
2025 Q2	$187K	Buy	+16,409	New	+$177K	﹤0.01%	3247
2025 Q1	–	Sell	-1,028	Closed	-$19.4K	–	3649
2024 Q4	$19.4K	Buy	+1,028	New	+$23.6K	﹤0.01%	3344

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Creative Planning's NRIX Position: Q1 2026 in Review

Creative Planning increased its Nurix Therapeutics (NRIX) stake by 5.6% in Q1 2026, buying an estimated $16.9K and bringing the position to 19,121 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #3436.

Creative Planning first reported a position in NRIX in Q4 2024 and has held it in 5 quarters since. The position peaked at $343K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Creative Planning held 19,121 shares of Nurix Therapeutics worth $296K as of Q1 2026.
Creative Planning bought 1,017 Nurix Therapeutics shares in Q1 2026, an estimated $16.9K.
Nurix Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3436 holding.
Creative Planning first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 5 quarters since.
Creative Planning's Nurix Therapeutics position peaked at $343K in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.